BioSPHEER™ 3D cancer model
Enhance predictive preclinical insight with our human-relevant tumor model
Enhance predictive preclinical insight with our human-relevant tumor model
Traditional preclinical models often fail to predict clinical outcomes.
2D cell cultures lack tumor complexity, while in vivo models, though biological relevant, are costly, time-consuming, and increasingly discouraged by regulators.
BioSPHEER™ is our in vitro 3D cancer platform — offering tailored tumor models that simulate the complexity and cellular diversity of solid tumors as they appear in the human body.
Built from spheroids composed of fibroblasts and cancer cells stimulating the formation of extracellular matrix, BioSPHEER™ more accurately mimics the tumor microenvironment, delivering predictive insights into drug efficacy earlier in development.
This enables faster, more confident decision-making, reduces reliance on animal studies, and supports alignment with FDA guidelines — calling for more predictive in vitro systems.
In this video, we explain why more predictive, human-relevant models are needed for studying solid tumors — and how BioSPHEER™ supports better decision-making in preclinical development.
You will see how our 3D models replicate the architecture and complexity of solid tumors than traditional 2D cultures, enabling more confident evaluation of therapeutic candidates.
Used by biotech and pharma for:
– Faster preclinical screening of drug candidates
– Mode of action studies
– Tailored tumor model development for complex indications
Choose between ready-to-use or tailored 3D tumor models
BioSPHEER™ offers access to a broad set of well-characterized 3D cancer models — ready for immediate use in evaluating drug candidates, including small molecules, biologics, antibody-drug-conjugates and advanced immune cell therapies like CAR T cells, under physiologically relevant conditions.
If you are working with a specific cancer cell line, therapeutic modality, or tumor type, our team can tailor a BioSPHEER™ model to match your needs. This includes optimized spheroid formation protocols and full access to our analytical toolbox — including imaging, molecular profiling, and functional assays.
The BioSPHEER™ 3D cancer models offer key advantages that align with evolving industry standards and regulatory expectations:
- Realistic human 3D tumor models – enabling more reliable drug testing
- Predictive insights into drug effect – supporting clinical confidence
- Cost-effective solution – cuts preclinical expenses
- Flexible & customizable setups – tailored to your therapy and tumor type
- Alternatives to animal testing – reduced reliance on animal use, aligned with the 3Rs principles and FDA/EMA guidance.
Applications of BioSPHEERTM 3D cancer models
Our 3D cancer models are enabling a wide range of applications in cancer and immuno-oncology research. Explore how BioSPHEER supports the full preclinical development pipeline:
Functional screening of drug modalities
Evaluate the efficacy of your therapeutic candidate with high-content, quantitative assays.
Our toolbox includes viability and apoptosis assays and cancer cell-specific killing readouts across both 2D and 3D models – supporting testing and evaluation of the entire spectrum of anti-cancer drugs from small molecules, biologics and antibody-drug-conjugates to immune cell mediated therapies like CAR T cells.
Drug target validation
Validate novel therapeutic targets using CRISPR-based knockouts in relevant cell lines or primary cells.
BioSPHEERTM enables precise modelling of disease mechanisms and quantification of functional effects using our complete set of assays for cellular and molecular analysis.
Drug mode of action studies
Understand how your therapy works within a complex 3D tumor microenvironment.
BioSPHEERTM supports immune-modulating agents and advanced therapies like CAR T cells through immune cell infiltration assays, phenotypic profiling, and immunofluorescence imaging — revealing key mechanisms of action in solid tumor settings.
Biomarker discovery and evaluation
Strengthen your translational insights with advanced biomarker profiling.
We offer whole transcriptome and targeted gene expression analyses, as well as multiplex cytokine readouts, supporting both discovery and validation of pharmacodynamic or response biomarkers.
Learn how our newest 3D cancer assays –with xCELLigence® RTCA eSight can help you
Our real-time assays reveal mechanisms that endpoint assays can´t capture. By continuously monitoring cellular behavior, they capture how tumor and immune cells grow, interact, and respond to treatment in real time.
Contact us for a free consultation
Interested in learning how BioSPHEER™ could support your project or pipeline?
We offer a free initial consultation to explore your needs.
For further information please contact Business Development Manager Philip Carlsen on pca@bioneer.dk or +4521679734
